JAK-STAT pathway in carcinogenesis: Is it relevant to cholangiocarcinoma progression

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 48

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

395

HTML

5199

Figures (1-3)

383

Tables (1-4)

237

Sum=6214

Dec 28, 2007 (publication date) through Dec 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Dec 28, 2007; 13(48): 6478-6491
Published online Dec 28, 2007. doi: 10.3748/wjg.v13.i48.6478

Table 2 Known components of JAK-STAT signaling for receptors expressed in cholangiocytes

Receptor type	JAK	STATs	Negative regulators of JAK-STAT signaling	References
Prolactin receptor	JAK2	STAT5 > STAT3 > STAT1	SOCS3, SOCS1, SOCS2, CIS	[47,48,51-53]
Growth hormone receptor	JAK2	STAT5 > STAT3 > STAT1	SOCS3, SOCS1, SOCS2, CIS	[70,71]
Leptin receptor	JAK2	STAT3 > STAT5, STAT6, STAT1	SOCS3	[74-79]
IL-6 receptor/gp130	JAK1, 2, Tyk2	STAT3 > STAT1	SOCS3	[15,18-20,101,102,110-112]
ErbB-2	No, JAK3, TYK2	STAT3 > STAT5, STAT6	SOCS3, SOCS1, SOCS4, SOCS5	[23,132-136,149,150]
c-Met	No	STAT3 > STAT5, STAT1	SOCS3	[115-122]

Citation: Smirnova OV, Ostroukhova TY, Bogorad RL. JAK-STAT pathway in carcinogenesis: Is it relevant to cholangiocarcinoma progression. World J Gastroenterol 2007; 13(48): 6478-6491
URL: https://www.wjgnet.com/1007-9327/full/v13/i48/6478.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i48.6478